Breast Cancer Clinical Trial
— YO-HAI5Official title:
Randomized Trial Comparing 5 and 15 Fractions for Whole Breast Irradiation After Breast Conserving Surgery
Verified date | March 2024 |
Source | University Hospital, Ghent |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Adjuvant radiotherapy after breast-conserving surgery for breast cancer reduces the risk of locoregional relapse and ensures better overall survival. In recent years it has been found that hypofractionation in which the number of radiation sessions is reduced with a higher dose per session offers advantages for breast irradiation. Randomized studies showed that moderate hypofraction regimens in 15 or 16 fractions have the same effect in tumor control and toxicity, although the total dose is lower than the traditional 50 Gy in 25 fractions. In a randomized study from the United Kingdom (START-B trial) even a better disease-free survival was seen with 15 sessions than with 25 sessions and the long-term side effects were also less with the short schedule. This project proposes a clinical trial with an accelerated radiotherapy schedule in 5 sessions. It is expected that the accelerated schedule of 5 sessions over 12 days will have a number of radiobiological benefits: since a higher dose per session is given over a shorter period of time, it is expected that tumor control and survival will be higher. By reducing the total treatment time, the total dose is reduced, which may result in fewer radiation-related side effects and thus improve the quality of life. Apart from these radiobiological benefits, the shorter radiotherapy program reduces the number of treatment days from 15 to 5. This is not only more comfortable for the patients, but also increases the treatment capacity of the radiotherapy department. This opens up a possibility for the use of more complex techniques with fewer side effects such as radiation in the prone position. This project includes a randomized study comparing the accelerated schedule in 5 sessions with a hypofraction schedule of 15 sessions in patients who are irradiated on the entire breast after breast-saving surgery. The primary endpoint is chest retraction (loss of volume) 2 years after radiotherapy.
Status | Completed |
Enrollment | 488 |
Est. completion date | June 23, 2023 |
Est. primary completion date | June 23, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - female patients with non-metastatic breast cancer, - age = 18 years, - breast conserving surgery, - multidisciplinary decision of adjuvant breast irradiation, - informed consent obtained, signed and dated before specific protocol procedures Exclusion Criteria: - lymph node metastases, - distant metastases, - bilateral breast irradiation, - history of previous radiation treatment to the same region - life expectancy of less than 2 years, - planned reconstructive surgery, - conditions making toxicity evaluation difficult (e.g. skin disorders), - inability to respect constraints on organs at risks - patients unlikely to comply with the protocol |
Country | Name | City | State |
---|---|---|---|
Belgium | Radiotherapie UZ Gent | Gent | Oost-Vlaanderen |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Ghent | Kom Op Tegen Kanker |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | radiation-induced breast retraction | The primary endpoint of the randomized trial is radiation-induced breast retraction (volume loss) measured 2 years after radiotherapy.$ | 4 years | |
Secondary | Acute breast toxicity: dermatitis | Dermatitis, Common Terminology Criteria for Adverse Events v4.03 | 2 years | |
Secondary | Acute breast toxicity: desquamation | Desquamation, Common Terminology Criteria for Adverse Events v4.03 | 2 years | |
Secondary | Acute breast toxicity: breast oedema | Oedema, Common Terminology Criteria for Adverse Events v4.03 | 2 years | |
Secondary | Acute breast toxicity: breast symptoms | pain, sense of heaviness, itching | 2 years | |
Secondary | Acute breast toxicity: dyspnoea | Dyspnoea, Common Terminology Criteria for Adverse Events v4.03 | 2 years | |
Secondary | Acute breast toxicity: cough | Cough, Common Terminology Criteria for Adverse Events v4.03 | 2 years | |
Secondary | Acute breast toxicity: pain | Pain, Common Terminology Criteria for Adverse Events v4.03 | 2 years | |
Secondary | Late toxicity other than breast retraction: breast oedema | Breast oedema, Common Terminology Criteria for Adverse Events v4.03 | 5 years | |
Secondary | Late toxicity other than breast retraction: telangiectasia | Telangiectasia, Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA) scales | 5 years | |
Secondary | Late toxicity other than breast retraction: colour changes | Colour changes, Common Terminology Criteria for Adverse Events v4.03 | 5 years | |
Secondary | Late toxicity other than breast retraction: fibrosis | Fibrosis, Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA) scales | 5 years | |
Secondary | Late toxicity other than breast retraction: breast symptoms | Pain, sense of heaviness, itching | 5 years | |
Secondary | Late toxicity other than breast retraction: dyspnoe | Dyspnoe, Common Terminology Criteria for Adverse Events v4.03 | 5 years | |
Secondary | Late toxicity other than breast retraction: pain | Pain, Common Terminology Criteria for Adverse Events v4.03 | 5 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |